According to Epax, in the year 2022, 96.7% of the by-products resulting from the manufacturing of its marine oil ingredients have been used for the creation of other valuable resources such as animal feed, fertilizer, and biogas.
Epax has announced in its first annual "Environment, Social, and Governance Report" that it is on the cusp of total circularity for its marine biomaterials. The company attributes this to its strict zero-waste policy. According to Epax, in the year 2022, 96.7% of the by-products resulting from the manufacturing of its marine oil ingredients have been used for the creation of other valuable resources such as animal feed, fertilizer, and biogas. The company is now committing to increase the amount of byproducts it reuses and recycles to 98% by the end of 2023.
Other efforts at sustainability highlighted in the report are the use of hydropower to reduce CO2 emmissions. According to Epax, 50% of its energy comes from hydropower, which has reduced the use of fuel oil by the company by 33% since 2019. This represents a 13.3% cut in CO2 emissions, according to the company’s press release. Epax is also using seawater off its own docks for cooling, reducing the company’s consumption of potable water by 5.7%.
“Epax has a long-standing commitment to sustainability, and an exceptionally high level of biocircularity is a key element of our plans for the future,” said Bjørn Refsum, CEO of Epax, in a press release. “This is increasingly important as consumer demand grows for sustainably produced omega-3 products and full ingredient transparency. To our knowledge, we’re the first supplier in the sector to report on our progress towards full circularity, but we hope that others will now do the same.”
In the report, Epax sets out to achieve 12 goals by the year 2030, including 100% renewable energy usage in the Epax’s Ålesund factory by 2025, and the use of 80% less potable water by 2025, compared to 2021. The company also hopes to achieve absolute reduction of CO2 emissions year-on-year by 2030.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.